TARGINIQ Drug Patent Profile
✉ Email this page to a colleague
When do Targiniq patents expire, and when can generic versions of Targiniq launch?
Targiniq is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are two patents protecting this drug.
This drug has one hundred and fifty-one patent family members in forty-one countries.
The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this compound. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Targiniq
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be March 30, 2025. This may change due to patent challenges or generic licensing.
There have been twenty-eight patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TARGINIQ?
- What are the global sales for TARGINIQ?
- What is Average Wholesale Price for TARGINIQ?
Summary for TARGINIQ
International Patents: | 151 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 5 |
Patent Applications: | 7 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TARGINIQ |
What excipients (inactive ingredients) are in TARGINIQ? | TARGINIQ excipients list |
DailyMed Link: | TARGINIQ at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TARGINIQ
Generic Entry Date for TARGINIQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, EXTENDED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for TARGINIQ
TARGINIQ is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TARGINIQ is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TARGINIQ
Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Oxycodone compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Expired US Patents for TARGINIQ
International Patents for TARGINIQ
See the table below for patents covering TARGINIQ around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Georgia, Republic of | P20074022 | PHARMACEUTICAL FORMULATIONS COMPRISING OXYCODONE AND NALOXONE | ⤷ Sign Up |
European Patent Office | 1730151 | PROCEDE DE PREPARATION D'HYDROCHLORURE D'OXYCODONE PRESENTANT MOINS DE 25 PPM DE 14-HYDROXYCODEINONE (PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE) | ⤷ Sign Up |
Japan | 2012188439 | PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 ppm 14-HYDROXYCODEINONE | ⤷ Sign Up |
Japan | 2001526228 | ⤷ Sign Up | |
Japan | 2016222732 | 乱用防止制御放出オピオイド投薬形態 (ABUSE-RESISTANT CONTROLLED-RELEASE OPIOID DOSAGE FORM) | ⤷ Sign Up |
Portugal | 2305683 | ⤷ Sign Up | |
Denmark | 2426132 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TARGINIQ
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1685839 | CA 2013 00052 | Denmark | ⤷ Sign Up | PRODUCT NAME: KOMBINATION AF OXYCODON SOM KOMPONENT A OG NALOXON SOM KOMPONENT B, HERUNDER OXYCODONHYDROCHLORID OG NALOXONHYDROCHLORIDDIHYDRAT; NAT. REG. NO/DATE: 43673, 43674 20081117; FIRST REG. NO/DATE: DE 64537.00.00, 64538.00.00, 64540.00.00, 64541.00.00 20060530 |
1685839 | 92292 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
1685839 | C300619 | Netherlands | ⤷ Sign Up | PRODUCT NAME: EEN COMBINATIE VAN OXYCODON ALS COMPONENT A EN NALOXON ALS COMPONENT B IN ALLE VORMEN ZOALS DEZE DOOR HET BASIS OCTROOI ONDER BESCHERMING WORDEN GESTELD; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 20060530 |
1685839 | 122013000082 | Germany | ⤷ Sign Up | PRODUCT NAME: KOMBINATION VON OXYCODON ALS KOMPONENTE A UND NALOXON ALS KOMPONENTE B IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: 64537.00.00 64538.00.00 64540.00.00 64541.00.00 73083.00.00 73084.00.00 73085.00.00 73086.00.00 20060530 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |